CDH1 and gastric cancer: Importantly, clinical-pathological evaluation demonstrated that patients with genomically stable gastric cancer—characterized by CDH1 loss and predominantly manifesting as DGC—showed significantly attenuated responses to immunotherapy [2, 35, 36].